NRP1 and glioblastoma: Moreover, the humanized VEGF antibody bevacizumab reduces glioblastoma multiforme (GBM) tumor growth but followed by tumor recurrence, possibly due to the ongoing autocrine signaling through the VEGF-VEGFR2–Neuropilin-1 (NRP1) axis, which is associated with the enrichment of active VEGFR2 GSC subset in human GBM cells [56].